RhumbLine Advisers’s HOOKIPA Pharma HOOK Stock Holding History

RhumbLine Advisers’s Portfolio HOOK Stock Details HOOK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-1,412	Closed	-$32K	–	3154
2022 Q1	$32K	Sell	1,412 -62	-4%	-$1.11K	﹤0.01%	2994
2021 Q4	$34K	Sell	1,474 -10	-0.7%	-$402	﹤0.01%	2993
2021 Q3	$87K	Buy	1,484 +145	+11%	+$10.5K	﹤0.01%	3003
2021 Q2	$123K	Buy	+1,339	New	+$179K	﹤0.01%	2959
2020 Q3	–	Sell	-1,093	Closed	-$127K	–	3002
2020 Q2	$127K	Buy	+1,093	New	+$107K	﹤0.01%	2916

Other funds holding HOOK

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

RhumbLine Advisers's HOOK Position: Q2 2022 in Review

RhumbLine Advisers sold out of HOOKIPA Pharma (HOOK) in Q2 2022, closing a stake of 1,412 shares — an estimated $32K sold.

RhumbLine Advisers first reported a position in HOOK in Q2 2020 and held it in 5 quarters. The position peaked at $127K in Q2 2020. 58 funds tracked by Wall St. Rank hold HOOK as of Q2 2022.

RhumbLine Advisers reported no remaining HOOKIPA Pharma position as of Q2 2022 after selling out during the quarter.
RhumbLine Advisers sold 1,412 HOOKIPA Pharma shares in Q2 2022, an estimated $32K.
RhumbLine Advisers first reported a position in HOOKIPA Pharma in Q2 2020 and held it in 5 quarters.
RhumbLine Advisers's HOOKIPA Pharma position peaked at $127K in Q2 2020.
58 funds tracked by Wall St. Rank held HOOKIPA Pharma as of Q2 2022.

Based on RhumbLine Advisers's 13F filing for Q2 2022, filed 11 Aug 2022.